Mitchell Cairo
Welcome,         Profile    Billing    Logout  
 21 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cairo, Mitchell S
NCT03805581: Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Completed
2
20
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University
Sickle Cell Disease, Acute Chest Syndrome
07/22
11/23
NCT02117297: SCT Plus Immune Therapy in Average Risk AML/MDS

Completed
2
26
US
Gemtuzumab Ozogamicin, Mylotarg
New York Medical College
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
03/23
03/23
NCT02221310: Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Completed
2
25
US
Gemtuzumab Ozogamicin, Mylotarg
New York Medical College
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/23
04/23
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
HaploSCD, NCT01461837: Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Active, not recruiting
2
21
US
CD34 selected T-cell depleted allogeneic SCT, Familial haploidentical, T-cell depleted, allogeneic stem cell transplantation, high risk Sickle Cell Disease
New York Medical College, UCSF Benioff Children's Hospital Oakland, Medical College of Wisconsin, Washington University School of Medicine, Tufts Medical Center, University of California, San Francisco, University of California, Los Angeles, Miltenyi Biomedicine GmbH, Ann & Robert H Lurie Children's Hospital of Chicago
Sickle Cell Disease
12/24
12/25
NCT03266640: Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Recruiting
2
20
US
viral specific cytotoxic t-lymphocytes, CMV CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, Washington University School of Medicine, Indiana University, Children's Hospital Los Angeles
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
08/24
12/24
NCT03266627: Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Recruiting
2
20
US
cytotoxic t-lymphocytes, viral specific CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, University of Colorado, Denver, Indiana University, Washington University School of Medicine, University of California, Los Angeles
Adenovirus, Primary Immune Deficiency Disorder
08/24
12/24
NCT03266653: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Recruiting
2
20
US
cytotoxic t-lymphocytes, CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Indiana University, Washington University School of Medicine, University of California, Los Angeles, University of California, San Francisco
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
08/24
12/25
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
NYMC-571, NCT02675959: Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Recruiting
2
40
US
Defibrotide
New York Medical College, University of California, Los Angeles, Medical College of Wisconsin, Tufts Medical Center, Baylor College of Medicine, Johns Hopkins University, Dana-Farber Cancer Institute, Children's Hospital Los Angeles
Sickle Cell Disease
12/24
12/25
NCT04099966: AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Recruiting
2
20
US
alpha beta depletion, α/β CD3+/CD19+ cell depletion
Mitchell Cairo
Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease, Beta-Thalassemia
12/25
12/26
NCT05987124: Defibrotide Dose-escalation for SOS Post-HSCT

Recruiting
2
20
US
Defibrotide, Defitelio
New York Medical College
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
08/26
08/27
NCT05564598: CMV CTLs in Neonates With CMV Infection

Recruiting
2
23
US
CMV Cytotoxic T-Lymphocytes, CTLs, Anti-viral Therapy, valganciclovir, ganciclovir
New York Medical College
Congenital Cytomegaloviral (CMV) Disease
10/27
10/28
RADICAL, NCT05253495: Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting
2
80
US
DOC Group B, Reduction Phase, Pv-COMRAD 1 and 2 Group B, Induction 1 and 2, Pv-R-CYM 1 and 2 Group B, Consolidation 1 and 2, DOC Group C, Reduction with IT, MAD CPR 1 and 2, Induction 1 and 2 Group C, Pv-R CYVE 1 and 2, Consolidation 1 and 2 Group C CNS Negative, Pv-R CYVE-MTX 1 and 2, Consolidation 1 and 2 Group C CNS Positive, MAD CP, Maintenance 1 Group C, Pv-Cytarabine/etoposide, Maintenance 2, 4 Group C, AD CP, Maintenance 3 Group C, Bv-AVD-R 1 and 2: COHORT IIa, Intermediate Risk cohort IIa, Bv-NVD-R, Cycle 1-2, Cohort IIa Rapid Early Responders, Bv-NVD-R, Cycle 1-4 SER, Cohort IIa Slow Early Responders, Bv-AVD-R, High-Risk cohort IIb, Bv-NVD-R, Cycle 1-4 RER, cohort IIb Rapid Early Responders, Bv-NAVD-R, Cycle 1-2, cohort IIb Slow Early Responders, Involved Site Radiation Therapy, Cohort II ONLY
New York Medical College
Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/27
06/28
NCT02098512: Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Active, not recruiting
1/2
20
US
Brentuximab Vedotin, Adcetris, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
New York Medical College, St. Baldrick's Foundation
Hodgkin Lymphoma
12/21
12/22
NCT04197596: Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Recruiting
1/2
40
US
BK CTL
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco
Viral Infection, Primary Immune Deficiency Disorder
12/24
06/25
NCT04896606: SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

Recruiting
1/2
50
US
Standard of Care, SARS-CoV2-CTLS
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital
Covid19
12/24
12/25
NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting
1/2
86
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
09/25
09/25
NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting
1/2
95
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, FACT Complex-targeting Curaxin CBL0137, CBL0137
Children's Oncology Group, Incuron LLC, National Cancer Institute (NCI)
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
12/26
12/26
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT03719105: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Recruiting
1
40
US
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
New York Medical College, University of Alabama at Birmingham
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
12/25
12/26
ALLO-T-DART, NCT04972942: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Recruiting
1
30
US
Daratumumab, Darzalex®
New York Medical College
T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
09/27
09/28
NCI-2022-03576, NCT05359237: Vincristine Pharmacokinetics in Infants

Recruiting
N/A
74
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Vincristine, LCR, Leurocristine, VCR, Vincrystine
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
07/24
07/24
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
D'Souza, Marise
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
Milner, Jordan
TransIT, NCT05600426: A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (, BMT CTN 2202)

Recruiting
3
234
US
cyclosporine, Matched Unrelated Donor Hematopoetic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), ATGAM, rabbit anti-thymocyte globulin (ATG), thymoglobulin, Methotrexate, Fludarabine, Cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Boston Children's Hospital, Center for International Blood and Marrow Transplant Research, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), North American Pediatric Aplastic Anemia Consortium, Pediatric Transplantation and Cellular Therapy Consortium, Blood and Marrow Transplant Clinical Trials Network
Severe Aplastic Anemia
12/29
12/29
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Recruiting
2
20
US
Miltenyi CliniMACS Prodigy ® system
University of Florida, Florida Department of Health
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
05/26
05/27
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NCT05322850: Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Suspended
1/2
40
US
Orca-Q
University of Florida, Orca Biosystems, Inc., Florida Department of Health
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
09/26
09/27
NYMC207, NCT04323748: Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Recruiting
1
20
US
rituxan, rituximab
New York Medical College
Immune Thrombocytopenic Purpura
07/24
07/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Cowles, Heather
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
Schaefer, Edo
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24

Download Options